Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Promotes anchorage-independent cell growth and tumor formation (By similarity).. Additionally we are shipping KIAA1524 Antibodies (80) and KIAA1524 Kits (9) and many more products for this protein.
Showing 4 out of 4 products:
Study revealed that the mechanism underlying the involvement of CIP2A in cisplatin sensitivity enhancement is that CIP2A mediates cisplatininduced cell apoptosis and DNA damage.
Aberrant expression of cancerous inhibitor of protein phosphatase 2A (CIP2A) indicates poor prognosis and promotes EMT and metastasis.
CIP2A overexpression is associated with lung metastasis in colorectal cancer .
MycN/CIP2A-mediated cell-fate bias may reflect a possible mechanism underlying early priming of some aggressive forms of neuroblastoma.
that CIP2A plays an important role in the carcinogenesis of endometrioid adenocarcinoma
CIP2A has higher expression in DDP-resistant GC patients. DDP-resistant GC patients with high CIP2A expression presented with poorer overall survival rates than those with low CIP2A expression.
High CIP2A expression is associated with laryngeal carcinoma.
High expression of CIP2A is associated with cisplatin resistant gastric cancer.
These data reveal that CIP2A is a crucial mediator of FN-induced bladder cancer cell proliferation via enhancing the stabilization of beta-catenin.
confirmed the high mRNA and protein expression levels of CIP2A in hepatocellular carcinoma (HCC), and found high CIP2A mRNA expression level was associated with unfavorable overall and recurrence-free survival in patients with HCC
High CIP2A expression is associated with gemcitabine resistance in pancreatic cancer.
These results are the first evidence that the inhibition of HDAC1 by (S)-2 downregulates CIP2A transcription
Membranous CIP2A expression as a potential novel prognostic and predictive indicator for tamoxifen resistance.
Cip2a effectively promotes triple-negative breast cancer (TNBC) cell cycle progression and tumor growth via regulation of PP2A/c-myc/p27Kip1 signaling, which could serve as a potential therapeutic target for TNBC patients.
poor prognosis of chronic myeloid leukemia patients with high CIP2A levels is due to an antiapoptotic phenotype
Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56
CIP2A is upregulated in MM, and CIP2A expression promotes cell proliferation and clonogenic formation ability by regulating the expression of AKT phosphorylation and c-Myc.
Gambogenic acid is a CIP2A inhibitor that interferes with the ubiquitination and destabilization of CIP2A.
Silencing CIP2A enhanced CuB-induced growth inhibition.
CIP2A copy number increase is associated with poor patient survival in human HNSCC.
CIP2A acts as a scaffold for CEP192-mediated microtubule organizing center assembly by recruiting Plk1 and aurora A during meiotic maturation in mouse oocytes
Knockdown of CIP2A by stable CIP2A siRNA transfection inhibited MDA-MB-231 cell proliferation, invasion, colony growth in vitro, and xenograft growth and metastasis in vivo of breast cancer in mice.
CIP2A as a hitherto unrecognized mediator of T-cell activation.
Downregulation of CIP2A suppresses cell proliferation and growth of nasopharyngeal carcinoma.
CIP2A strongly interacts with NEK2 during G2/M phase, thereby enhancing NEK2 kinase activity to facilitate centrosome separation in a PP1- and PP2A-independent manner.
Data show that CIP2A expression can be systematically inhibited without severe consequences to normal mouse development and viability may have clinical relevance regarding targeting of oncogenic CIP2A for future cancer therapies.
Loss of CIP2A in Myc-overexpressing neural progenitor cells significantly reduces the ability of Myc to increase self-renewal and proliferation.
Promotes anchorage-independent cell growth and tumor formation (By similarity).
cancerous inhibitor of PP2A
, p90 autoantigen
, protein CIP2A
, p90 autoantigen homolog
, protein CIP2A homolog
, CONSTANS interacting protein 2a
, hypothetical protein LOC100216050